Cooperative properties of cytochromes P450

Pharmacology and Therapeutics

Volumn 124, Issue 2, 2009, Pages 151-167

  Denisov, Ilia G ^a   Frank, Daniel J ^a   Sligar, Stephen G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Allosteric effects; Cooperativity; Drug drug interactions; P450

Indexed keywords

7 ETHOXYCOUMARIN; AFLATOXIN B1; AMITRIPTYLINE; ANTIBIOTIC AGENT; BROMOCRIPTINE; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAPSONE; DIAZEPAM; DICLOFENAC; ENZYME; ERYTHROMYCIN; ESTRADIOL; FLURBIPROFEN; HALOPERIDOL; HEME OXYGENASE; IBUPROFEN; KETOCONAZOLE; MIDAZOLAM; MONOMER; NAPROXEN; NIFEDIPINE; PALMITIC ACID; PARACETAMOL; PROGESTERONE; TESTOSTERONE; UNINDEXED DRUG;

DRUG BINDING SITE; DRUG PROTEIN BINDING; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; HETEROTROPHY; HUMAN; MICHAELIS MENTEN KINETICS; MOLECULAR MECHANICS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; STEROIDOGENESIS; STOICHIOMETRY; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; LIGANDS; MODELS, CHEMICAL; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 69249241970     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.05.011     Document Type: Review

References (218)

1. Aburto J., Correa-Basurto J., and Torres E. Atypical kinetic behavior of chloroperoxidase-mediated oxidative halogenation of polycyclic aromatic hydrocarbons. Arch Biochem Biophys 480 (2008) 33-40
2. Ackers G.K. Deciphering the molecular code of hemoglobin allostery. Adv Protein Chem 51 (1998) 185-253
3. Afshar M., and Thormann W. Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: evidence for atypical kinetics by CYP2D6 and CYP3A4. Electrophoresis 27 (2006) 1526-1536
4. Ainslie Jr. G.R., Shill J.P., and Neet K.E. Transients and cooperativity. A slow transition model for relating transients and cooperative kinetics of enzymes. J Biol Chem 247 (1972) 7088-7096
5. Andersson T., Miners J.O., Veronese M.E., and Birkett D.J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38 (1994) 131-137
6. Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., and Kamataki T. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 281 (2001) 1256-1260
7. Atkins W.M. Non-Michaelis-Menten kinetics in cytochrome P 450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45 (2005) 291-310
8. Atkins W.M. Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin Drug Metab Toxicol 2 (2006) 573-579
9. Baas B.J., Denisov I.G., and Sligar S.G. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys 430 (2004) 218-228
10. Bachmann K.A., Ring B.J., and Wrighton S.A. Drug-drug interactions and the cytochromes P450. In: Lee J.S., Obach R.S., and Fisher M.B. (Eds). Drug Metabolizing Enzymes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development (2003), CRC Press, Boca Raton, FL 311-336
11. Backes W.L., Batie C.J., and Cawley G.F. Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4-1A2 complex with a high affinity for NADPH-cytochrome P450 reductase. Biochemistry 37 (1998) 12852-12859
12. Bardsley W.G. Factorability of the allosteric binding polynomial and graphical manifestations of cooperativity in third degree saturation functions. J Theor Biol 67 (1977) 407-431
13. Bardsley W.G., and Wyman J. Concerning the thermodynamic definition and graphical manifestations of positive and negative co-operativity. J Theor Biol 72 (1978) 373-376
14. Ben-Naim A. Cooperativity and Regulation in Biochemical Processes (2001), Kluwer Academic/Plenum Publishers, New York
15. Biskup C., Kusch J., Schulz E., Nache V., Schwede F., Lehman F., et al. Relating ligand binding to activation gating in CNGA2 channels. Nature 446 (2007) 440-443
16. Brown H.S., Galetin A., Hallifax D., and Houston J.B. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45 (2006) 1035-1050
17. Cameron M.D., Wen B., Allen K.E., Roberts A.G., Schuman J.T., Campbell A.P., et al. Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry 44 (2005) 14143-14151
18. Cameron M.D., Wen B., Roberts A.G., Atkins W.M., Campbell A.P., and Nelson S.D. Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site. Chem Res Toxicol 20 (2007) 1434-1441
19. Carr B.A., Norcross R., Fang Y., Lu P., Rodrigues A.D., Shou M., et al. Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34 (2006) 1703-1712
20. Cawley G.F., Zhang S., Kelley R.W., and Backes W.L. Evidence supporting the interaction of CYP2B4 and CYP1A2 in microsomal preparations. Drug Metab Dispos 29 (2001) 1529-1534
21. Collom S.L., Laddusaw R.M., Burch A.M., Kuzmic P., Perry Jr. M.D., and Miller G.P. CYP2E1 substrate inhibition: mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem 283 (2008) 3487-3496
22. Connors K.A. Binding Constants: The Measurement of Molecular Complex Stability (1987), Wiley Interscience, New York
23. Cornish-Bowden A., and Koshland Jr. D.E. Diagnostic uses of the Hill (Logit and Nernst) plots. J Mol Biol 95 (1975) 201-212
24. Coryell C.D. Existence of chemical interactions between the hemes (hemins) in ferrihemoglobin (methemoglobin) and the role of interactions in the interpretation of ferro-ferrihemoglobin electrode potential measurements. J Phys Chem 43 (1939) 841-852
25. Cupp-Vickery J., Anderson R., and Hatziris Z. Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity. Proc Natl Acad Sci U S A 97 (2000) 3050-3055
26. Cupp-Vickery J.R., and Poulos T.L. Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nat Struct Biol 2 (1995) 144-153
27. Dabrowski M.J., Schrag M.L., Wienkers L.C., and Atkins W.M. Pyrene-pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc 124 (2002) 11866-11867
28. Davydov D.R., Baas B.J., Sligar S.G., and Halpert J.R. Allosteric mechanisms in cytochrome P450 3A4 studied by high-pressure spectroscopy: pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket. Biochemistry 46 (2007) 7852-7864
29. Davydov D.R., Botchkareva A.E., Davydova N.E., and Halpert J.R. Resolution of two substrate-binding sites in an engineered cytochrome P450eryF bearing a fluorescent probe. Biophys J 89 (2005) 418-432
30. Davydov D.R., Botchkareva A.E., Kumar S., He Y.Q., and Halpert J.R. An electrostatically driven conformational transition is involved in the mechanisms of substrate binding and cooperativity in cytochrome P450eryF. Biochemistry 43 (2004) 6475-6485
31. Davydov D.R., Davydova N.Y., and Halpert J.R. Allosteric transitions in cytochrome P450eryF explored with pressure-perturbation spectroscopy, lifetime FRET, and a novel fluorescent substrate, Fluorol-7GA. Biochemistry 47 (2008) 11348-11359
32. Davydov D.R., Davydova N.Y., Tsalkova T.N., and Halpert J.R. Effect of glutathione on homo- and heterotropic cooperativity in cytochrome P450 3A4. Arch Biochem Biophys 471 (2008) 134-145
33. Davydov D.R., and Halpert J.R. Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?. Expert Opin Drug Metab Toxicol 4 (2008) 1523-1535
34. Davydov D.R., Halpert J.R., Renaud J.P., and Hui Bon Hoa G. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem Biophys Res Commun 312 (2003) 121-130
35. Davydov D.R., Kumar S., and Halpert J.R. Allosteric mechanisms in P450eryF probed with 1-pyrenebutanol, a novel fluorescent substrate. Biochem Biophys Res Commun 294 (2002) 806-812
36. Denisov I.G., Baas B.J., Grinkova Y.V., and Sligar S.G. Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation. J Biol Chem 282 (2007) 7066-7076
37. Denisov I.G., Grinkova Y.V., McLean M.A., and Sligar S.G. The one-electron autoxidation of human cytochrome P450 3A4. J Biol Chem 282 (2007) 26865-26873
38. Di Cera E. Thermodynamics of local linkage effects. Contracted partition functions and the analysis of site-specific energetics. Biophys Chem 37 (1990) 147-164
39. Di Cera E. Thermodynamic Theory of Site-specific Binding Processes in Biological Macromolecules (1995), Cambridge University Press, Cambridge
40. Di Cera E. Site-specific thermodynamics: understanding cooperativity in molecular recognition. Chem Rev 98 (1998) 1563-1591
41. Di Cera E., Page M.J., Bah A., Bush-Pelc L.A., and Garvey L.C. Thrombin allostery. Phys Chem Chem Phys 9 (2007) 1291-1306
42. Di Cera E. Thrombin. Mol Aspects Med 29 (2008) 203-254
43. Di Marco A., Marcucci I., Verdirame M., Perez J., Sanchez M., Pelaez F., et al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab Dispos 33 (2005) 349-358
44. Ding Y., Seufert W.H., Beck Z.Q., and Sherman D.H. Analysis of the cryptophycin P450 epoxidase reveals substrate tolerance and cooperativity. J Am Chem Soc 130 (2008) 5492-5498
45. Domanski T.L., He Y.A., Harlow G.R., and Halpert J.R. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J Pharmacol Exp Ther 293 (2000) 585-591
46. Domanski T.L., He Y.A., Khan K.K., Roussel F., Wang Q., and Halpert J.R. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 40 (2001) 10150-10160
47. Egnell A.-C., Eriksson C., Albertson N., Houston B., and Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307 (2003) 878-887
48. Egnell A.C., Houston J.B., and Boyer C.S. Predictive models of CYP3A4 heteroactivation: in vitro-in vivo scaling and pharmacophore modeling. J Pharmacol Exp Ther 312 (2005) 926-937
49. Ekins S., Vandenbranden M., Ring B.J., Gillespie J.S., Yang T.J., Gelboin H.V., et al. Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286 (1998) 1253-1259
50. Ekins S., and Wrighton S.A. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31 (1999) 719-754
51. Ekroos M., and Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 103 (2006) 13682-13687
52. Emoto C., and Iwasaki K. Enzymic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36 (2006) 219-233
53. Emoto C., Yamazaki H., Iketaki H., Yamasaki S., Satoh T., Shimizu R., et al. Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 31 (2001) 265-275
54. Fernando H., Halpert J.R., and Davydov D.R. Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry 45 (2006) 4199-4209
55. Fernando H., Davydov D.R., Chin C.C., and Halpert J.R. Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W. Arch Biochem Biophys 460 (2007) 129-140
56. Fisher H.F., Gates R.E., and Cross D.G. A ligand exclusion theory of allosteric effects. Nature 228 (1970) 247-249
57. Forsen S., and Linse S. Cooperativity: over the Hill. Trends Biochem Sci 20 (1995) 495-497
58. Galetin A., Clarke S.E., and Houston J.B. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30 (2002) 1512-1522
59. Galetin A., Clarke S.E., and Houston J.B. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31 (2003) 1108-1116
60. Galetin A., Ito K., Hallifax D., and Houston J.B. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314 (2005) 180-190
61. Gillam E.M., Wunsch R.M., Ueng Y.F., Shimada T., Reilly P.E., Kamataki T., et al. Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch Biochem Biophys 346 (1997) 81-90
62. Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., and Wrighton S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47 (1994) 1643-1653
63. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharm Toxicol 39 (1999) 1-17
64. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14 (2001) 611-650
65. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz de Montellano P.R. (Ed). Cytochrome P450: Structure, Mechanism, and Biochemistry (2005), Kluwer Academic/Plenum Publishers, New York 377-530
66. Gustafsson M.C.U., Roitel O., Marshall K.R., Noble M.A., Chapman S.K., Pessegueiro A., et al. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium. Biochemistry 43 (2004) 5474-5487
67. Gutheil W.G. Reformulation of thermodynamic systems with aggregation and theoretical methods for the analysis of ligand binding in proteins with monomer-multimer equilibria. Biophys Chem 52 (1994) 83-95
68. Harlow G.R., and Halpert J.R. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci U S A 95 (1998) 6636-6641
69. Harrelson J.P., Henne K.R., Alonso D.O.V., and Nelson S.D. A comparison of substrate dynamics in human CYP2E1 and CYP2A6. Biochem Biophys Res Commun 352 (2007) 843-849
70. Harrelson J.P., Atkins W.M., and Nelson S.D. Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Biochemistry 47 (2008) 2978-2988
71. Hays A.A., Dunn A.R., Chiu R., Gray H.B., Stout C.D., and Goodin D.B. Conformational states of cytochrome P450cam revealed by trapping of synthetic molecular wires. J Mol Biol 344 (2004) 455-469
72. Hazai E., Bikadi Z., Simonyi M., and Kupfer D. Association of cytochrome P450 enzymes is a determining factor in their catalytic activity. J Comput Aided Mol Des 19 (2005) 271-285
73. Heinrich R., Schuster S., and Holzhuetter H.G. Mathematical analysis of enzymic reaction systems using optimization principles. Eur J Biochem 201 (1991) 1-21
74. Hill A.V. The combinations of haemoglobin with oxygen and with carbon monoxide. Biochem J 7 (1913) 471-480
75. Hill T.L. Cooperativity theory in biochemistry. Steady-state and Equilibrium Systems (1985), Springer-Verlag, New York
76. Hill T.L., Eisenberg E., and Chalovich J.M. Theoretical models for cooperative steady-state ATPase activity of myosin subfragment-1 on regulated actin. Biophys J 35 (1981) 99-112
77. Hinz H.J., and Sturtevant J.M. Calorimetric studies of dilute aqueous suspensions of bilayers formed from synthetic L-α-lecithins. J Biol Chem 247 (1972) 6071-6075
78. Hlavica P., and Lewis D.F. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. Eur J Biochem 268 (2001) 4817-4832
79. Hosea N.A., Miller G.P., and Guengerich F.P. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39 (2000) 5929-5939
80. Houston J.B., and Galetin A. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433 (2005) 351-360
81. Houston J.B., and Kenworthy K.E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28 (2000) 246-254
82. Houston J.B., Kenworthy K.E., and Galetin A. Typical and atypical enzyme kinetics. In: Lee J.S., Obach R.S., and Fisher M.B. (Eds). Drug Metabolizing Enzymes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development (2003), CRC Press, Boca Raton, FL 211-254
83. Huang M.T., Chang R.L., Fortner J.G., and Conney A.H. Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. J Biol Chem 256 (1981) 6829-6836
84. Huang W.C., Westlake A.C., Marechal J.D., Joyce M.G., Moody P.C., and Roberts G.C. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency. J Mol Biol 373 (2007) 633-651
85. Hummel M.A., Gannett P.M., Aguilar J.S., and Tracy T.S. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 43 (2004) 7207-7214
86. Hummel M.A., Locuson C.W., Gannett P.M., Rock D.A., Mosher C.M., Rettie A.E., et al. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68 (2005) 644-651
87. Hutzler J.M., Frye R.F., Korzekwa K.R., Branch R.A., Huang S.M., and Tracy T.S. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci 14 (2001) 47-52
88. Hutzler J.M., Hauer M.J., and Tracy T.S. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Disp 29 (2001) 1029-1034
89. Hutzler J.M., Wienkers L.C., Wahlstrom J.L., Carlson T.J., and Tracy T.S. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 410 (2003) 16-24
90. Ingelman-Sundberg M., and Johansson I. Catalytic properties of purified forms of rabbit liver microsomal cytochrome P-450 in reconstituted phospholipid vesicles. Biochemistry 19 (1980) 4004-4011
91. Isin E.M., and Guengerich F.P. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 281 (2006) 9127-9136
92. Isin E.M., and Guengerich F.P. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4. J Biol Chem 282 (2007) 6863-6874
93. Isin E.M., and Guengerich F.P. Substrate binding to cytochromes P450. Anal Bioanal Chem 392 (2008) 1019-1030
94. Isin E.M., Sohl C.D., Eoff R.L., and Guengerich F.P. Cooperativity of cytochrome P450 1A2: interactions of 1,4-phenylene diisocyanide and 1-isopropoxy-4-nitrobenzene. Arch Biochem Biophys 473 (2008) 69-75
95. Jamakhandi A.P., Kuzmic P., Sanders D.E., and Miller G.P. Global analysis of protein-protein interactions reveals multiple CYP2E1-reductase complexes. Biochemistry 46 (2007) 10192-10201
96. Johnson E.A., Tanford C., and Reynolds J.A. Variable stoichiometry in active ion transport: theoretical analysis of physiological consequences. Proc Natl Acad Sci U S A 82 (1985) 5352-5356
97. Johnson E.F., Schwab G.E., and Dieter H.H. Allosteric regulation of the 16 alpha-hydroxylation of progesterone as catalyzed by rabbit microsomal cytochrome P-450 3b. J Biol Chem 258 (1983) 2785-2788
98. Johnson E.F., Schwab G.E., and Vickery L.E. Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. J Biol Chem 263 (1988) 17672-17677
99. Johnson E.F., and Stout C.D. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Comm 338 (2005) 331-336
100. Jones M.N. The thermal behavior of lipids and biological membranes. In: Jones M.N. (Ed). Biochemical Thermodynamics (1979), Elsevier Scientific, Amsterdam 185-223
101. Jushchyshyn M.I., Hutzler J.M., Schrag M.L., and Wienkers L.C. Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys 438 (2005) 21-28
102. Kantrowitz E.R., and Lipscomb W.N. Escherichia coli aspartate transcarbamoylase: the molecular basis for a concerted allosteric transition. Trends Biochem Sci 15 (1990) 53-59
103. Kapelyukh Y., Paine M.J.I., Marechal J.D., Sutcliffe M.J., Wolf C.R., and Roberts G.C.K. Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab Dispos 36 (2008) 2136-2144
104. Kelley R.W., Reed J.R., and Backes W.L. Effects of ionic strength on the functional interactions between CYP2B4 and CYP1A2. Biochemistry 44 (2005) 2632-2641
105. Kelley R.W., Cheng D., and Backes W.L. Heteromeric complex formation between CYP2E1 and CYP1A2: evidence for the involvement of electrostatic interactions. Biochemistry 45 (2006) 15807-15816
106. Kenworthy K.E., Bloomer J.C., Clarke S.E., and Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48 (1999) 716-727
107. Kenworthy K.E., Clarke S.E., Andrews J., and Houston J.B. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 29 (2001) 1644-1651
108. Kerlan V., Dreano Y., Bercovici J.P., Beaune P.H., Floch H.H., and Berthou F. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 44 (1992) 1745-1756
109. Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J., et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47 (1994) 1969-1979
110. Khan K.K., and Halpert J.R. 7-Benzyloxyquinoline oxidation by P450eryF A245T: finding of a new fluorescent substrate probe. Chem Res Toxicol 15 (2002) 806-814
111. Khan K.K., He Y.A., He Y.Q., and Halpert J.R. Site-directed mutagenesis of cytochrome P450eryF: implications for substrate oxidation, cooperativity, and topology of the active site. Chem Res Toxicol 15 (2002) 843-853
112. Khan K.K., Liu H., and Halpert J.R. Homotropic versus heterotopic cooperativity of cytochrome P450eryF: a substrate oxidation and spectral titration study. Drug Metab Disp 31 (2003) 356-359
113. Kim C., Kim H., and Han O. The role of serine-246 in cytochrome P450eryF-catalyzed hydroxylation of 6-deoxyerythronolide B. Biosci Biotech Biochem 65 (2001) 752-757
114. Kim D., Cryle M.J., De Voss J.J., and Ortiz de Montellano P.R. Functional expression and characterization of cytochrome P450 52A21 from Candida albicans. Arch Biochem Biophys 464 (2007) 213-220
115. Kitada M., Kamataki T., Itahashi K., Rikihisa T., Kato R., and Kanakubo Y. Purification and properties of cytochrome P-450 from homogenates of human fetal livers. Arch Biochem Biophys 241 (1985) 275-280
116. Klotz I.M., and Hunston D.L. Protein interactions with small molecules. Relationships between stoichiometric binding constants, site binding constants, and empirical binding parameters. J Biol Chem 250 (1975) 3001-3009
117. Klotz I.M. Ligand-Receptor Energetics: A Guide for the Perplexed (1997), Wiley and Sons, New York
118. Konecny J., Jurica J., Tomandl J., and Glatz Z. Study of recombinant cytochrome P450 2C9 activity with diclofenac by MEKC. Electrophoresis 28 (2007) 1229-1234
119. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37 (1998) 4137-4147
120. Koshland Jr. D.E., and Hamadani K. Proteomics and models for enzyme cooperativity. J Biol Chem 277 (2002) 46841-46844
121. Krauser J.A., and Guengerich F.P. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 280 (2005) 19496-19506
122. Kudo S., and Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 54 (1998) 253-259
123. Lampe J.N., and Atkins W.M. Time-resolved fluorescence studies of heterotropic ligand binding to cytochrome P450 3A4. Biochemistry 45 (2006) 12204-12215
124. Lane A.N. The dependence of flux, sensitivity and response of the flux on the concentrations of substrate and modifiers for cooperative enzymes. J Theor Biol 99 (1982) 491-508
125. Lawson R.J., Leys D., Sutcliffe M.J., Kemp C.A., Cheesman M.R., Smith S.J., et al. Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis. Biochemistry 43 (2004) 12410-12426
126. Li H., and Poulos T.L. The structure of the cytochrome p450BM-3 hemedomain complexed with the fatty acid substrate, palmitoleic acid. Nat Struct Biol 4 (1997) 140-146
127. Li Q.S., Ogawa J., Schmid R.D., and Shimizu S. Indole hydroxylation by bacterial cytochrome P450 BM-3 and modulation of activity by cumene hydroperoxide. Biosci Biotechnol Biochem 69 (2005) 293-300
128. Li Y., Yokoi T., Katsuki M., Wang J.S., Groopman J.D., and Kamataki T. In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene. Cancer Res 57 (1997) 641-645
129. Locuson C.W., Gannett P.M., and Tracy T.S. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch Biochem Biophys 449 (2006) 115-129
130. Makino M., Sugimoto H., Shiro Y., Asamizu S., Onaka H., and Nagano S. Crystal structures and catalytic mechanism of cytochrome P450 StaP that produces the indolocarbazole skeleton. Proc Natl Acad Sci U S A 104 (2007) 11591-11596
131. Mansuy D. Biocatalysis and substrate chemodiversity: adaptation of aerobic living organisms to their chemical environment. Catal Today 138 (2008) 2-8
132. McConn II D.J., Lin Y.S., Allen K., Kunze K.L., and Thummel K.E. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32 (2004) 1083-1091
133. Miller G.P. Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. Expert Opin Drug Metab Toxicol 4 (2008) 1053-1064
134. Miller G.P., and Guengerich F.P. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. Biochemistry 40 (2001) 7262-7272
135. Modi S., Gilham D.E., Sutcliffe M.J., Lian L.Y., Primrose W.U., Wolf C.R., et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 36 (1997) 4461-4470
136. Muralidhara B.K., and Halpert J.R. Thermodynamics of ligand binding to P450 2B4 and P450eryF studied by isothermal titration calorimetry. Drug Metab Rev 39 (2007) 539-556
137. Muralidhara B.K., Negi S.S., and Halpert J.R. Dissecting the thermodynamics and cooperativity of ligand binding in cytochrome P450eryF. J Am Chem Soc 129 (2007) 2015-2024
138. Nakamura H., Torimoto N., Ishii I., Ariyoshi N., Nakasa H., Ohmori S., et al. CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Disp 31 (2003) 432-438
139. Nath A., Fernandez C., Lampe J.N., and Atkins W.M. Spectral resolution of a second binding site for Nile Red on cytochrome P4503A4. Arch Biochem Biophys 474 (2008) 198-204
140. Nath A., Grinkova Y.V., Sligar S.G., and Atkins W.M. Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem 282 (2007) 28309-28320
141. Nath A., Koo P.K., Rhoades E., and Atkins W.M. Allosteric effects on substrate dissociation from cytochrome P450 3A4 in nanodiscs observed by ensemble and single-molecule fluorescence spectroscopy. J Am Chem Soc 130 (2008) 15746-15747
142. Niwa T., Murayama N., and Yamazaki H. Heterotropic cooperativity in oxidation mediated by cytochrome P450. Curr Drug Metab 9 (2008) 453-462
143. Niwa T., Okada K., Hiroi T., Imaoka S., Narimatsu S., and Funae Y. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 31 (2008) 348-351
144. Obach R.S., Walsky R.L., Venkatakrishnan K., Gaman E.A., Houston J.B., and Tremaine L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316 (2006) 336-348
145. Oda Y., and Kharasch E.D. Metabolism of levo-alpha-acetylmethadol (LAAM) by human liver cytochrome p450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites. J Pharmacol Exp Ther 297 (2001) 410-422
146. Ogu C.C., and Maxa J.L. Drug interactions due to cytochrome P450. Proc Bayl Univ Med Cent 13 (2000) 421-423
147. Okada Y., Murayama N., Yanagida C., Shimizu M., Guengerich F.P., and Yamazaki H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab Dispos 37 (2009) 18-23
148. Otyepka M., Skopalik J., Anzenbacherova E., and Anzenbacher P. What common structural features and variations of mammalian P450s are known to date?. Biochim Biophys Acta 1770 (2007) 376-389
149. Ouellet H., Podust L.M., and Ortiz de Montellano P.R. Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs. J Biol Chem 283 (2008) 5069-5080
150. Park S.Y., Yamane K., Adachi S.I., Shiro Y., Weiss K.E., Maves S.A., et al. Thermophilic cytochrome P450 (CYP119) from Sulfolobus solfataricus: high resolution structure and functional properties. J Inorg Biochem 91 (2002) 491-501
151. Pauling L. The oxygen equilibrium of hemoglobin and its structural interpretation. Proc Natl Acad Sci U S A 21 (1935) 186-191
152. Perutz M.F. Mechanisms of cooperativity and allosteric regulation in proteins. Q Rev Biophys 22 (1989) 139-237
153. Podust L.M., Bach H., Kim Y., Lamb D.C., Arase M., Sherman D.H., et al. Comparison of the 1.85 A structure of CYP154A1 from Streptomyces coelicolor A3(2) with the closely related CYP154C1 and CYPs from antibiotic biosynthetic pathways. Protein Sci 13 (2004) 255-268
154. Podust L.M., Kim Y., Arase M., Neely B.A., Beck B.J., Bach H., et al. The 1.92-A structure of Streptomyces coelicolor A3(2) CYP154C1. A new monooxygenase that functionalizes macrolide ring systems. J Biol Chem 278 (2003) 12214-12221
155. Pylypenko O., and Schlichting I. Structural aspects of ligand binding to and electron transfer in bacterial and fungal P450s. Annu Rev Biochem 73 (2004) 991-1018
156. Reinhart G.D. The determination of thermodynamic allosteric parameters of an enzyme undergoing steady-state turnover. Arch Biochem Biophys 224 (1983) 389-401
157. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34 (2002) 83-448
158. Roberts A.G., and Atkins W.M. Energetics of heterotropic cooperativity between alpha-naphthoflavone and testosterone binding to CYP3A4. Arch Biochem Biophys 463 (2007) 89-101
159. Roberts A.G., Campbell A.P., and Atkins W.M. The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. Biochemistry 44 (2005) 1353-1366
160. Rock D., Wahlstrom J., and Wienkers L. Cytochrome P450s: drug-drug interactions. In: Vaz R.J., and Klabunde T. (Eds). Antitargets. Prediction and Prevention of Drug Side Effects Vol. 38 (2008), Wiley-VCH Verlag, Darmstadt 197-246
161. Rock D.A., Perkins B.N.S., Wahlstrom J., and Jones J.P. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy w product formation. Arch Biochem Biophys 416 (2003) 9-16
162. Rostovtseva T.K., Liu T.T., Colombini M., Parsegian V.A., and Bezrukov S.M. Positive cooperativity without domains or subunits in a monomeric membrane channel. Proc Natl Acad Sci U S A 97 (2000) 7819-7822
163. Rowland P., Blaney F.E., Smyth M.G., Jones J.J., Leydon V.R., Oxbrow A.K., et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 281 (2006) 7614-7622
164. Schoch G.A., Yano J.K., Sansen S., Dansette P.M., Stout C.D., and Johnson E.F. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283 (2008) 17227-17237
165. Schoch G.A., Yano J.K., Wester M.R., Griffin K.J., Stout C.D., and Johnson E.F. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279 (2004) 9497-9503
166. Schrag M.L., and Wienkers L.C. Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). Drug Metab Dispos 28 (2000) 1198-1201
167. Schwab G.E., Raucy J.L., and Johnson E.F. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33 (1988) 493-499
168. Scott E.E., He Y.Q., and Halpert J.R. Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F-G region in P450 2B1. Chem Res Toxicol 15 (2002) 1407-1413
169. Scott E.E., White M.A., He Y.A., Johnson E.F., Stout C.D., and Halpert J.R. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-Chlorophenyl)imidazole at 1.9-.ANG. Resolution: insight into the range of P450 conformations and the coordination of redox. J Biol Chem 279 (2004) 27294-27301
170. Segel I.H. Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-state Enzyme Systems (1975), Wiley Interscience, New York
171. Sherman D.H., Li S., Yermalitskaya L.V., Kim Y., Smith J.A., Waterman M.R., et al. The structural basis for substrate anchoring, active site selectivity, and product formation by P450 PikC from Streptomyces venezuelae. J Biol Chem 281 (2006) 26289-26297
172. Shimada T., Yamazaki H., Foroozesh M., Hopkins N.E., Alworth W.L., and Guengerich F.P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem Res Toxicol 11 (1998) 1048-1056
173. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
174. Shou M. The impact of cytochrome P450 allosterism on pharmacokinetics and drug-drug interactions. Drug Discov Today 9 (2004) 636-637
175. Shou M., Dai R., Cui D., Korzekwa K.R., Baillie T.A., and Rushmore T.H. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276 (2001) 2256-2262
176. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33 (1994) 6450-6455
177. Shou M., Mei Q., Ettore Jr. M.W., Dai R., Baillie T.A., and Rushmore T.H. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 340 (1999) 845-853
178. Sligar S.G., and Denisov I.G. Understanding cooperativity in human P450 mediated drug-drug interactions. Drug Metab Rev 39 (2007) 567-579
179. Sohl C.D., Isin E.M., Eoff R.L., Marsch G.A., Stec D.F., and Guengerich F.P. Cooperativity in oxidation reactions catalyzed by cytochrome P450 1A2: highly cooperative pyrene hydroxylation and multiphasic kinetics of ligand binding. J Biol Chem 283 (2008) 7293-7308
180. Spatzenegger M., Liu H., Wang Q., Debarber A., Koop D.R., and Halpert J.R. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J Pharmacol Exp Ther 304 (2003) 477-487
181. Strushkevich N., Usanov S.A., Plotnikov A.N., Jones G., and Park H.W. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol 380 (2008) 95-106
182. Szklarz G.D., and Halpert J.R. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. Drug Metab Dispos 26 (1998) 1179-1184
183. Tang W., and Stearns R.A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2 (2001) 185-198
184. Torres E., and Aburto J. Chloroperoxidase-catalyzed oxidation of 4,6-dimethyldibenzothiophene as dimer complexes: evidence for kinetic cooperativity. Arch Biochem Biophys 437 (2005) 224-232
185. Tracy T.S. Atypical cytochrome p450 kinetics: implications for drug discovery. Drugs R D 7 (2006) 349-363
186. Tracy T.S., and Hummel M.A. Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab Rev 36 (2004) 231-242
187. Tracy T.S., Hutzler J.M., Haining R.L., Rettie A.E., Hummel M.A., and Dickmann L.J. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30 (2002) 385-390
188. Tsalkova T.N., Davydova N.Y., Halpert J.R., and Davydov D.R. Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe. Biochemistry 46 (2007) 106-119
189. Uchaipichat V., Galetin A., Houston J.B., Mackenzie P.I., Williams J.A., and Miners J.O. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74 (2008) 1152-1162
190. Ueng Y.F., Kuwabara T., Chun Y.J., and Guengerich F.P. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36 (1997) 370-381
191. Ueng Y.F., Shimada T., Yamazaki H., and Guengerich F.P. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol 8 (1995) 218-225
192. van Vugt-Lussenburg B.M., Damsten M.C., Maasdijk D.M., Vermeulen N.P., and Commandeur J.N. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem Biophys Res Commun 346 (2006) 810-818
193. von Koenig K., and Schlichting I. Cytochromes P450 - structural basis for binding and catalysis. In: Sigel A., Sigel H., and Sigel R.K.O. (Eds). Ubiquitous Roles of Cytochrome P450 Proteins. Metal Ions in Life Sciences Vol. 3 (2007), Wiley and Sons, Chichester 235-265
194. Wade R.C., Winn P.J., Schlichting I., and Sudarko. A survey of active site access channels in cytochromes P450. J Inorg Biochem 98 (2004) 1175-1182
195. Wang Y., and Unadkat J.D. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos 20 (1999) 341-346
196. Wang R.W., Newton D.J., Liu N., Atkins W.M., and Lu A.Y. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28 (2000) 360-366
197. Warrilow A.G., Jackson C.J., Parker J.E., Marczylo T.H., Kelly D.E., Lamb D.C., et al. Identification, characterization and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae. Antimicrob Agents Chemother 53 (2009) 1157-1164
198. Waterman M.R., and Lepesheva G.I. Sterol 14alpha-demethylase, an abundant and essential mixed-function oxidase. Biochem Biophys Res Commun 338 (2005) 418-422
199. Wei L., Locuson C.W., and Tracy T.S. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol 72 (2007) 1280-1288
200. Wester M.R., Johnson E.F., Marques-Soares C., Dansette P.M., Mansuy D., and Stout C.D. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3.ANG. resolution: evidence for multiple substrate binding modes. Biochemistry 42 (2003) 6370-6379
201. Wester M.R., Johnson E.F., Marques-Soares C., Dijols S., Dansette P.M., Mansuy D., et al. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1.ANG. resolution: evidence for an induced fit model of substrate binding. Biochemistry 42 (2003) 9335-9345
202. Westlake A.C.G., Harford-Cross C.F., Donovan J., and Wong L.L. Mutations of glutamate-84 at the putative potassium-binding site affect camphor binding and oxidation by cytochrome P450cam. Eur J Biochem 265 (1999) 929-935
203. Williams P.A., Cosme J., Vinkovic D.M., Ward A., Angove H.C., Day P.J., et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305 (2004) 683-686
204. Winzor D.J., and Sawyer W.H. Quantitative Characterization of Ligand Binding (1995), Wiley-Liss, New York
205. Woodbury C.P. Introduction to Macromolecular Binding Equilibria (2008), CRC Press, Boca Raton
206. Xiang H., Tschirret-Guth R.A., and Ortiz de Montellano P.R. An A245T mutation conveys on cytochrome P450eryF the ability to oxidize alternative substrates. J Biol Chem 275 (2000) 35999-36006
207. Yamazaki H., Ueng Y.F., Shimada T., and Guengerich F.P. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34 (1995) 8380-8389
208. Yano J.K., Hsu M.H., Griffin K.J., Stout C.D., and Johnson E.F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12 (2005) 822-823
209. Yano J.K., Koo L.S., Schuller D.J., Li H., Ortiz de Montellano P.R., and Poulos T.L. Crystal structure of a thermophilic cytochrome P450 from the archaeon Sulfolobus solfataricus. J Biol Chem 275 (2000) 31086-31092
210. Yoon M.Y., Campbell A.P., and Atkins W.M. "Allosterism" in the elementary steps of the cytochrome P450 reaction cycle. Drug Metab Rev 36 (2004) 219-230
211. Youdim K.A., Zayed A., Dickins M., Phipps A., Griffiths M., Darekar A., et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 65 (2008) 680-692
212. Zanger U.M., Turpeinen M., Klein K., and Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392 (2008) 1093-1108
213. Zhang Z., Li Y., Shou M., Zhang Y., Ngui J.S., Stearns R.A., et al. Influence of different recombinant systems on the cooperativity exhibited by cytochrome P450 3A4. Xenobiotica 34 (2004) 473-486
214. Zhao B., Guengerich F.P., Bellamine A., Lamb D.C., Izumikawa M., Lei L., et al. Binding of two flaviolin substrate molecules, oxidative coupling, and crystal structure of Streptomyces coelicolor A3(2) cytochrome P450 158A2. J Biol Chem 280 (2005) 11599-11607
215. Zhao B., Lamb D.C., Lei L., Kelly S.L., Yuan H., Hachey D.L., et al. Different binding modes of two flaviolin substrate molecules in cytochrome P450 158A1 (CYP158A1) compared to CYP158A2. Biochemistry 46 (2007) 8725-8733
216. Zhao Y., White M.A., Muralidhara B.K., Sun L., Halpert J.R., and Stout C.D. Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem 281 (2006) 5973-5981
217. Zhao Y., and Halpert J.R. Structure-function analysis of cytochromes P450 2B. Biochim Biophys Acta 1770 (2007) 402-412
218. Zimm B.H., and Bragg J.K. Theory of the phase transition between helix and random coil in polypeptide chains. J Chem Phys 31 (1959) 526-535